COVID-19 in patients with rheumatic disease in Hubei province, China: a multicentre retrospective observational study
et al., Lancent Rheumatology,
Rheumatic disease patients on HCQ had a lower risk of COVID-19 than those on other disease-modifying anti-rheumatic drugs, OR 0.09 (0.01–0.94), p=0.044 after adjusting for age, sex, smoking, systemic lupus erythematosus, infection in other family members, and comorbidities. 43 patients with rheumatic disease and COVID-19 exposure.
risk of case, 91.0% lower, RR 0.09, p = 0.04, treatment 7 of 16 (43.8%), control 20 of 27 (74.1%), NNT 3.3, adjusted per study.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Zhong et al., 3 Jul 2020, retrospective, database analysis, China, peer-reviewed, 20 authors.